Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
BioCardia, Inc. BCDA
$2.04
+$0.04 (1.88%)
На 17:46, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
39179240.00000000
-
week52high
2.60
-
week52low
1.10
-
Revenue
1352000
-
P/E TTM
-3
-
Beta
1.01418600
-
EPS
-0.67000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 10:59
Описание компании
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 20 дек 2021 г. | |
| Dawson James | Neutral | Buy | 16 апр 2021 г. |
| Maxim Group | Buy | 25 ноя 2020 г. | |
| Brookline Capital | Buy | 25 ноя 2020 г. | |
| Alliance Global Partners | Buy | 25 ноя 2020 г. | |
| Dawson James | Neutral | Buy | 11 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| FROST PHILLIP MD ET AL | A | 2025827 | 595238 | 16 дек 2022 г. |
| McClung David | A | 87446 | 8928 | 16 дек 2022 г. |
| STERTZER SIMON H | A | 888084 | 178571 | 16 дек 2022 г. |
| Altman Peter | A | 347827 | 14880 | 16 дек 2022 г. |
| Blank Andrew Scott | A | 291659 | 148809 | 16 дек 2022 г. |
| Allen Jim L. | A | 830531 | 148809 | 16 дек 2022 г. |
| Altman Peter | A | 332947 | 1400 | 11 ноя 2022 г. |
| Altman Peter | A | 331547 | 3100 | 10 ноя 2022 г. |
| McClung David | A | 78518 | 2000 | 10 окт 2022 г. |
| Altman Peter | A | 328447 | 1400 | 23 сент 2022 г. |
Новостная лента
BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023
GlobeNewsWire
03 мая 2023 г. в 20:00
SUNNYVALE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three months ended March 31, 2023 and provide a corporate update by conference call on Wednesday, May 10, 2023 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.
BioCardia, Inc. (BCDA) Q4 2022 Earnings Call Transcript
Seeking Alpha
29 мар 2023 г. в 22:38
BioCardia, Inc. (NASDAQ:BCDA ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Peter Altman - President & CEO David McClung - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright Kumaraguru Raja - Roth Capital James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by.
BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023
GlobeNewsWire
16 мар 2023 г. в 07:00
SUNNYVALE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2022 and provide a corporate update conference call on Wednesday, March 29, 2023 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.
BioCardia, Inc. (BCDA) Q3 2022 Earnings Call Transcript
Seeking Alpha
12 ноя 2022 г. в 20:52
BioCardia, Inc. (NASDAQ:BCDA ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Jules Abraham - CORE IR Peter Altman - President & CEO David McClung - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright Michael Okunewitch - Maxim James Molloy - Alliance Global Partners Operator Good day, and welcome to the BioCardia 2022 Third Quarter Conference Call.
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
09 ноя 2022 г. в 18:48
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?